MX2016015218A - Antibioticos macrociclicos de amplio espectro. - Google Patents

Antibioticos macrociclicos de amplio espectro.

Info

Publication number
MX2016015218A
MX2016015218A MX2016015218A MX2016015218A MX2016015218A MX 2016015218 A MX2016015218 A MX 2016015218A MX 2016015218 A MX2016015218 A MX 2016015218A MX 2016015218 A MX2016015218 A MX 2016015218A MX 2016015218 A MX2016015218 A MX 2016015218A
Authority
MX
Mexico
Prior art keywords
broad spectrum
compounds
spectrum antibiotics
macrocyclic
macrocyclic broad
Prior art date
Application number
MX2016015218A
Other languages
English (en)
Inventor
Bradley Schwarz Jacob
Ly Cuong
Curran Roberts Tucker
Andrew Smith Peter
I Higuchi Robert
Paraselli Prasuna
Bergeron Philippe
F T Koehler Michael
Hu Huiyong
Crawford James
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016015218A publication Critical patent/MX2016015218A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proporcionan compuestos antibacterianos, en que los compuestos en algunas realizaciones tienen bioactividad de amplio espectro. En diversas realizaciones, los compuestos actúan mediante la inhibición de la peptidasa señal de tipo 1 bacteriana (SpsB), una proteína esencial en bacterias. También se proporcionan composiciones farmacéuticas y métodos para el tratamiento usando los compuestos descritos en el presente documento.
MX2016015218A 2014-05-20 2015-05-19 Antibioticos macrociclicos de amplio espectro. MX2016015218A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000980P 2014-05-20 2014-05-20
US201562142404P 2015-04-02 2015-04-02
PCT/US2015/031631 WO2015179441A2 (en) 2014-05-20 2015-05-19 Macrocyclic broad spectrum antibiotics

Publications (1)

Publication Number Publication Date
MX2016015218A true MX2016015218A (es) 2017-07-04

Family

ID=54554959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016015218A MX2016015218A (es) 2014-05-20 2015-05-19 Antibioticos macrociclicos de amplio espectro.

Country Status (10)

Country Link
US (1) US10392422B2 (es)
EP (1) EP3145944B1 (es)
JP (2) JP6823588B2 (es)
KR (1) KR20170027721A (es)
CN (1) CN106661084B (es)
BR (1) BR112016027232A2 (es)
CA (1) CA2949681A1 (es)
MX (1) MX2016015218A (es)
RU (1) RU2016146581A (es)
WO (1) WO2015179441A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
JP6823588B2 (ja) 2014-05-20 2021-02-03 アールキューエックス ファーマシューティカルズ，インク． 大環状広域スペクトル抗生物質
TWI725075B (zh) * 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素
AU2016357926B2 (en) * 2015-11-20 2021-05-27 Genentech, Inc. Macrocyclic broad spectrum antibiotics
JPWO2017122697A1 (ja) * 2016-01-13 2018-12-06 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法、酸拡散制御剤及び化合物
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
WO2017156074A1 (en) * 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Calpain modulators and methods of production and use thereof
EP3481835A4 (en) 2016-07-05 2020-02-26 Blade Therapeutics, Inc. CALPAIN MODULATORS AND THEIR THERAPEUTIC USES
CN110023304A (zh) 2016-09-28 2019-07-16 布莱德治疗公司 钙蛋白酶调节剂及其治疗用途
EP3330260A1 (en) * 2016-12-01 2018-06-06 Enantia, S.L. Process for the preparation of an intermediate for the synthesis of i.a. carfilzomib
PE20191618A1 (es) 2017-02-15 2019-11-05 Rqx Pharmaceuticals Inc Antibioticos macrociclicos de amplio espectro
WO2018175173A1 (en) * 2017-03-21 2018-09-27 The Scripps Research Institute Cu-and ni-catalyzed decarboxylative borylation reactions
CN106966947B (zh) * 2017-03-30 2019-09-03 河北医科大学 一种维格列汀的制备方法
EP3724175A1 (en) * 2017-12-15 2020-10-21 Merck Patent GmbH Substituted aromatic amines for use in organic electroluminescent devices
CN108806787B (zh) * 2018-07-06 2022-04-05 上海长海医院 面向临床手术的医用耗材智能监控系统
CN109355404B (zh) * 2018-08-30 2022-03-29 华南理工大学 基于聚合酶螺旋反应恒温检测单增李斯特菌的引物、试剂盒及检测方法
EP3852786A4 (en) * 2018-09-19 2022-09-28 Georgia Tech Research Corporation SELF-DOSING BACTERIAL PROTEASE-ACTIVATED PRODRUG
AR119019A1 (es) * 2019-05-28 2021-11-17 Hoffmann La Roche Antibióticos macrocíclicos de amplio espectro

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3128280A (en) 1959-10-23 1964-04-07 Searle & Co 1-(alkoxylated/halogenated phenyl)-3-pyridylmethylureas
US5204328A (en) 1990-06-26 1993-04-20 Merck & Co., Inc. Peptides having atrial natriuretic factor activity
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
GB9902399D0 (en) 1999-02-03 1999-03-24 Smithkline Beecham Plc Compounds
US6660832B1 (en) 1999-08-20 2003-12-09 Isis Pharmaceuticals, Inc. Macrocyclic compounds and preparation methods thereof
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
DE10226921A1 (de) 2002-06-17 2003-12-24 Bayer Ag Antibakterielle Amid-Makrozyklen
NZ544750A (en) 2003-07-17 2009-06-26 Migenix Inc Compositions of amphomycin or aspartocin based lipopeptide antibiotic derivatives and methods of use thereof
DE10358824A1 (de) * 2003-12-16 2005-07-21 Bayer Healthcare Ag Antibakterielle Makrozyklen mit substituiertem Biphenyl
DE102005014245A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen V
DE102005014247A1 (de) 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Antibakterielle Amid-Makrozyklen VI
EP2542086A4 (en) 2010-03-01 2013-09-04 Myrexis Inc COMPOUNDS AND ITS THERAPEUTIC USE
KR20130028078A (ko) * 2010-03-09 2013-03-18 머크 캐나다 인크. 베타-락탐 항박테리아제의 활성을 강화시키는 가교된 리포글리코펩티드
WO2011120071A1 (en) 2010-04-01 2011-10-06 The University Of Queensland Oxytocin peptide analogues
US9187524B2 (en) * 2010-09-15 2015-11-17 The Scripps Research Institute Broad spectrum antibiotic arylomycin analogs
US10501493B2 (en) 2011-05-27 2019-12-10 Rqx Pharmaceuticals, Inc. Broad spectrum antibiotics
TWI642684B (zh) 2011-05-27 2018-12-01 Ｒｑｘ製藥股份有限公司 廣效性抗生素
CN104284664A (zh) * 2012-03-14 2015-01-14 斯克里普斯研究所 广谱抗生素Arylomycin类似物
CN103788176A (zh) 2012-10-31 2014-05-14 上海来益生物药物研究开发中心有限责任公司 一种arylomycin类化合物及其制备方法和应用
EP2922829B1 (en) * 2012-11-21 2021-08-11 RQX Pharmaceuticals, Inc. Macrocyclic broad spectrum antibiotics
JP6823588B2 (ja) 2014-05-20 2021-02-03 アールキューエックス ファーマシューティカルズ，インク． 大環状広域スペクトル抗生物質
ITUB20154591A1 (it) 2015-10-12 2017-04-12 Crestoptics S R L Apparato di microscopia confocale e relativo procedimento di acquisizione ed elaborazione di immagini
AU2016357926B2 (en) 2015-11-20 2021-05-27 Genentech, Inc. Macrocyclic broad spectrum antibiotics
TWI725075B (zh) 2015-11-20 2021-04-21 美商Ｒｑｘ製藥公司 巨環廣效抗生素

Also Published As

Publication number Publication date
KR20170027721A (ko) 2017-03-10
WO2015179441A3 (en) 2016-01-14
US20170088582A1 (en) 2017-03-30
CN106661084A (zh) 2017-05-10
EP3145944A2 (en) 2017-03-29
JP6823588B2 (ja) 2021-02-03
CA2949681A1 (en) 2015-11-26
WO2015179441A2 (en) 2015-11-26
EP3145944B1 (en) 2021-05-05
JP2021073210A (ja) 2021-05-13
RU2016146581A (ru) 2018-06-21
US10392422B2 (en) 2019-08-27
RU2016146581A3 (es) 2018-12-20
EP3145944A4 (en) 2018-01-03
CN106661084B (zh) 2021-08-31
BR112016027232A2 (pt) 2018-06-26
JP2017517567A (ja) 2017-06-29
JP7148652B2 (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
MX2016015218A (es) Antibioticos macrociclicos de amplio espectro.
MX2018006190A (es) Antibioticos de amplio espectro macrociclico.
MX2015006340A (es) Antibioticos macrociclicos de amplio espectro.
MX2018006199A (es) Antibioticos de amplio espectro macrociclico.
PH12016501577A1 (en) Monobactam organic compounds for the treatment of bacterial infections
MX2018003101A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
MX2019001125A (es) Inhibidores de cinasa macrociclica.
PH12019501904A1 (en) Macrocyclic broad spectrum antibiotics
WO2017083431A3 (en) Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
GEP20227406B (en) Chromane monobactam compounds for the treatment of bacterial infections
MX2021014554A (es) Antibioticos macrociclicos de amplio espectro.
AU2015352440B2 (en) Compounds
WO2017218922A8 (en) Compositions and methods for the treatment of bacterial infections
MX2017012073A (es) Compuestos de minociclina para biodefensas.
MX2016001927A (es) Antibióticos de péptidos lineales.
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
WO2019067498A3 (en) Peptide antibiotic complexes and methods of use thereof
MX2018011095A (es) Compuestos de carbapenem.
TN2021000092A1 (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof
PH12015500518A1 (en) Tricyclic tetrahydroquinoline antibacterial agents
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.
EP3538094A4 (en) FORMULATIONS, METHODS, KIT AND PHARMACEUTICAL FORMS FOR TREATING BACTERIAL INFECTIONS
WO2018211323A8 (en) Heterocyclic compounds for the treatment of disease
MX2019014475A (es) Formulaciones de lixivaptan para el tratamiento de enfermedades poliquisticas.